2014
DOI: 10.1148/radiol.14131946
|View full text |Cite
|
Sign up to set email alerts
|

Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: Treatment with Transarterial Chemoembolization Combined with Sorafenib—A Retrospective Controlled Study

Abstract: TACE-sorafenib side effects were acceptable, and this treatment may improve overall survival in patients with HCC with first-order or lower-branch PVTT when compared with patients who underwent TACE alone.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

9
150
4

Year Published

2015
2015
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 152 publications
(163 citation statements)
references
References 28 publications
9
150
4
Order By: Relevance
“…The OS of 6.0 months for sorafenib monotherapy is also lower than that reported in SHARP (Sorafenib in Advanced Hepatocellular Carcinoma) trial (OS: 10.7 months), but that study cohort only consisted of 36% patients with macroscopic vascular invasion [5]. The increased number of patients with MPVTT and underlying disease (hepatitis B and cirrhosis) in the present study might account for the poor survival, since those factors are known negative predictors for OS [14,21,22].…”
Section: Discussioncontrasting
confidence: 58%
See 2 more Smart Citations
“…The OS of 6.0 months for sorafenib monotherapy is also lower than that reported in SHARP (Sorafenib in Advanced Hepatocellular Carcinoma) trial (OS: 10.7 months), but that study cohort only consisted of 36% patients with macroscopic vascular invasion [5]. The increased number of patients with MPVTT and underlying disease (hepatitis B and cirrhosis) in the present study might account for the poor survival, since those factors are known negative predictors for OS [14,21,22].…”
Section: Discussioncontrasting
confidence: 58%
“…This contradicts studies showing the effectiveness of TACE combined with sorafenib for advanced HCC [13][14][15]. However, the inclusion of less advanced-stage patients with MPVTT in those studies could be a possible explanation for the contradictions.…”
Section: Discussionmentioning
confidence: 92%
See 1 more Smart Citation
“…The combination therapy using sorafenib and TACE appears to provide a survival benefit for patients with PVTT and adequate liver function. This benefit seems to be more pronounced in patients whose first-order or more distal branches of the portal vein are involved [50] than in patients with main portal vein involvement.…”
Section: [1]mentioning
confidence: 90%
“…Zhu et al [64] conducted a retrospective study comparing the efficacy and safety of TACE plus sorafenib in 91 HCC patients accompanying PVTT (46 TACE-sorafenib vs 45 TACE alone). TACE plus sorafenib showed significant survival benefits over TACE alone in patients with Vp3 (median OS, 13 mo vs 6 mo; P = 0.002) or Vp1-2 (median OS, 15 mo vs 10 mo; P = 0.003).…”
Section: Tace Combined With Sorafenibmentioning
confidence: 99%